Navigation Links
CorMatrix Cardiovascular to Present Data on Its Next Generation ECM Technology(TM) at Annual Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, D.C.
Date:10/10/2008

WASHINGTON, Oct. 10 /PRNewswire/ -- CorMatrix Cardiovascular, Inc., an Atlanta-based company dedicated to developing and delivering unique extracellular matrix (ECM(TM)) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, today announced that Robert G. Matheny, M.D., Chief Scientific Officer, will present data on the company's next generation ECM Technology(TM) at the annual Transcatheter Cardiovascular Therapeutics (TCT) 2008 conference in Washington, D.C. next week.

The presentation entitled "Cell Therapy Devices and Concepts: Acellular Matrix Emulsion Injections to Induce Myofibroblast Proliferation and Angiogenesis" will take place on Monday, October 13th at 1:35 p.m. EDT in room 145AB as part of the Innovative Devices and Futuristic Therapies Session.

"We are very proud to have Dr. Matheny included to present preclinical data from our next generation product within this prestigious panel," commented Beecher Lewis, President and Chief Operating Officer of CorMatrix Cardiovascular. "Our inclusion in this session reinforces the fact that our technology continues to gain interest and acceptance among the cardiovascular community."

About CorMatrix ECM Technology(TM)

CorMatrix Cardiovascular holds an exclusive license from Purdue University to research, develop, manufacture and market naturally occurring ECM products for cardiovascular applications. The company currently has U.S. clearance and European approval with a CE Mark to market its ECM Technology as an implant for pericardial closure, clearance in the U.S. for cardiac tissue repair, and is conducting preclinical studies on a number of cardiovascular applications including an emulsified, injectible form of its ECM Technology as a potential treatment for heart failure.

About CorMatrix Cardiovascular, Inc.

CorMatrix Cardiovascular, a privately held company based in Atlanta, Georgia, is dedicated to developing and delivering innovative biomaterial devices that harness the body's own innate ability to regenerate damaged heart tissue. For more information visit http://www.cormatrix.com.


'/>"/>
SOURCE CorMatrix Cardiovascular, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CorMatrix(R) Announces FDA 510(k) for Novel Biomaterial Implant for Intracardiac Repair
2. Core Laboratories Joint Venture Agreement Between genae associates, VIBGYOR Scientific Research, Cardiovascular Center Aalst and J.B. Dahm
3. Physician to Implant the CATANIA(TM) Coronary Stent System With Polyzene(R)-F to Treat Chronic Total Occlusion During Live Case at the Paris Cardiovascular Interventions Course (Francophone) 2008
4. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
5. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
6. Terumo Cardiovascular Systems Files Patent Infringement Complaint Against Maquet Affiliates
7. Expert Consensus Panel Recommendation for Incorporating Lp-PLA2 Testing into Cardiovascular Disease Risk Assessment Guidelines
8. HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker
9. The Gladstone Institutes and iZumi Bio Announce Broad Partnership in Regenerative Medicine and Cardiovascular Disease
10. Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
11. CardioVascular BioTherapeutics, Inc. Funding Wound Healing Trial with R&D Partnership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... NC (PRWEB) , ... June 27, 2016 , ... ... mission to bring innovative medical technologies, services and solutions to the healthcare market. ... and implementation of various distribution, manufacturing, sales and marketing strategies that are necessary ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
Breaking Biology Technology:
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/9/2016)... June 9, 2016  Perkotek an innovation leader in attendance control systems is proud ... work hours, for employers to make sure the right employees are actually signing in, ... ... ... ...
(Date:6/3/2016)... June 3, 2016 ... Nepal hat ein ... hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und ... der Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche ... im Januar teilgenommen, aber Decatur wurde als ...
Breaking Biology News(10 mins):